Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Revenue (2016 - 2025)

Enanta Pharmaceuticals' Revenue history spans 14 years, with the latest figure at $18.6 million for Q4 2025.

  • For Q4 2025, Revenue rose 9.76% year-over-year to $18.6 million; the TTM value through Dec 2025 reached $67.0 million, up 0.58%, while the annual FY2025 figure was $65.3 million, 3.42% down from the prior year.
  • Revenue reached $18.6 million in Q4 2025 per ENTA's latest filing, up from $15.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $27.6 million in Q4 2021 to a low of $14.6 million in Q3 2024.
  • Average Revenue over 5 years is $19.1 million, with a median of $18.7 million recorded in 2022.
  • The largest YoY upside for Revenue was 15.93% in 2021 against a maximum downside of 27.11% in 2021.
  • A 5-year view of Revenue shows it stood at $27.6 million in 2021, then fell by 14.7% to $23.6 million in 2022, then dropped by 23.67% to $18.0 million in 2023, then fell by 5.8% to $17.0 million in 2024, then rose by 9.76% to $18.6 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Revenue are $18.6 million (Q4 2025), $15.1 million (Q3 2025), and $18.3 million (Q2 2025).